Sanofi's rare disease drug Xenpozyme scores FDA approval after nods in Japan and Europe

On a campaign to develop first-in-class and best-in-class medicines, Sanofi has gained an FDA nod for its latest rare disease drug.

In March, regulators in Japan signed off on Xenpozyme to treat Niemann-Pick, a rare genetic disease that prevents the body from metabolizing fat and leads to premature death. Officials in Europe did the same two months later.